A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy delandistrogene moxeparvovec (Elevidys), Sarepta Therapeutics said in a statement Tuesday.

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the death Tuesday morning, sending the company's shares plummeting in morning trading.

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy treatment. The patient was a young man who suffered acute liver failure after being treated with Elevidys,